ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: BCR::ABL1-independent resistance is mediated through the activation of alternative survival pathways, such as changes in epigenetics, cellular signaling, the CML microenvironment, and transport protein expression [36,37].